A Clinical Utility Study of PrismRA for Rheumatoid Arthritis
NCT05161234 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 613
Last updated 2024-03-05
Summary
A clinical utility study for PrismRA testing therapeutic response in patients with rheumatoid arthritis.
Conditions
Sponsors & Collaborators
-
Scipher Medicine
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-03
- Primary Completion
- 2023-12-06
- Completion
- 2023-12-06
Countries
- United States
Study Locations
More Related Trials
-
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
NCT03147248 ·Status: COMPLETED ·Phase: PHASE3
-
Targeted Ultrasound in Rheumatoid Arthritis
NCT02056184 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
NCT02222493 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
NCT00144534 ·Status: COMPLETED ·Phase: PHASE3
-
Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis
NCT07293871 ·Status: RECRUITING ·Phase: PHASE2
-
Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
NCT01076959 ·Status: COMPLETED
-
INCB047986 in Rheumatoid Arthritis
NCT02151474 ·Status: TERMINATED ·Phase: PHASE2
-
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
NCT01217086 ·Status: COMPLETED ·Phase: PHASE3
-
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)
NCT00380601 ·Status: COMPLETED ·Phase: PHASE3
-
Infliximab for the Treatment of Early Rheumatoid Arthritis
NCT00006292 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis
NCT00760864 ·Status: COMPLETED ·Phase: PHASE2
-
RA-PRO PRAGMATIC TRIAL
NCT04692493 ·Status: RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment
NCT02837978 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
NCT07237659 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
NCT00144521 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of MTX Discontinuation on Shingrix Response in RA
NCT06574594 ·Status: RECRUITING ·Phase: NA
-
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
NCT01770379 ·Status: TERMINATED ·Phase: PHASE3
-
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
NCT02330445 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
NCT01332994 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis
NCT00458146 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
NCT02019472 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01347983 ·Status: COMPLETED ·Phase: PHASE3
-
Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis
NCT00213564 ·Status: COMPLETED
-
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
NCT00837434 ·Status: COMPLETED ·Phase: PHASE4
-
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
NCT07029555 ·Status: RECRUITING ·Phase: PHASE1